Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia ; volume:29 ; number:7 ; day:6 ; month:7 ; year:2023 ; pages:1700-1709 ; date:7.2023
Nature medicine ; 29, Heft 7 (6.7.2023), 1700-1709, 7.2023
- Urheber
-
Anderson, Nathaniel D.
Birch, Jack
Accogli, Theo
Criado, Ignacio
Khabirova, Eleonora
Parks, Conor
Wood, Yvette
Young, Matthew D.
Porter, Tarryn
Richardson, Rachel
Albon, Sarah J.
Popova, Bilyana
Lopes, Andre
Wynn, Robert
Hough, Rachael
Gohil, Satyen H.
Pule, Martin
Amrolia, Persis J.
Behjati, Sam
Ghorashian, Sara
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41591-023-02415-3
- URN
-
urn:nbn:de:101:1-2023102413025589413424
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:03 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Anderson, Nathaniel D.
- Birch, Jack
- Accogli, Theo
- Criado, Ignacio
- Khabirova, Eleonora
- Parks, Conor
- Wood, Yvette
- Young, Matthew D.
- Porter, Tarryn
- Richardson, Rachel
- Albon, Sarah J.
- Popova, Bilyana
- Lopes, Andre
- Wynn, Robert
- Hough, Rachael
- Gohil, Satyen H.
- Pule, Martin
- Amrolia, Persis J.
- Behjati, Sam
- Ghorashian, Sara
- SpringerLink (Online service)
Ähnliche Objekte (12)
Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease
Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T
CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation
Identification of genomic signatures in bone marrow associated with clinical response of CD19 CAR T-cell therapy
MIP3α as an early prognostic predictor for patients with B-cell malignancies receiving CD19/CD22-redirected CAR-T cell cocktail therapy
HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden
A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy
Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease
Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T
CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation
Identification of genomic signatures in bone marrow associated with clinical response of CD19 CAR T-cell therapy
MIP3α as an early prognostic predictor for patients with B-cell malignancies receiving CD19/CD22-redirected CAR-T cell cocktail therapy
HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden
A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy
Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease
Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T
CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation
Identification of genomic signatures in bone marrow associated with clinical response of CD19 CAR T-cell therapy
MIP3α as an early prognostic predictor for patients with B-cell malignancies receiving CD19/CD22-redirected CAR-T cell cocktail therapy
HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden